25 August 2022
Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer…
24 August 2022
Condensed half-yearly financial report 30 June 2022…
Camellia Plc (CAM.L) issues the following update on trading for the year and confirms the interim results release date….
23 August 2022
Unaudited half-year results for the six months ended 30th June 2022…
19 August 2022
“HICL” or the “Company” and, together with its subsidiaries, the “Group”, the London-listed infrastructure investment company managed by InfraRed Capital Partners Limited (“InfraRed” or the “Investment Manager”)….
17 August 2022
Preliminary Results for the year ended 30 April 2022…
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action that may address the significant unmet medical needs of myelofibrosis patients with anaemia. …
Statement: Zantac (ranitidine) U.S. litigation Notice of Voluntary Dismissal to be filed in Bayer case, first scheduled Zantac trial GSK did not settle Plaintiff…